ArticleACS omega2026
Engineering Three-Chamber Core-Sheath Cellulose Acetate Nanofibers via Multifluid Electrospinning for Enhanced Wettability and Tunable Initial Drug Release Behavior.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traditional materials are often constrained by their structural and functional limitations. To address this challenge, multifluid electrospinning has emerged as an advanced nanofabrication technique capable of producing complex structures with enhanced performance. Inspired by rocket stage separation, we utilized cellulose acetate, a biomacromolecule derivative, as the polymer matrix to fabricate complex three-chamber core-sheath nanofibers with TEM-verified structures and enhanced performance. The surface wettability of the fibers was effectively tuned by adjusting the polyvinylpyrrolidone (PVP) concentration in the outermost layer, where a higher PVP content enabled a rapid transition from hydrophobic to hydrophilic states. Furthermore, the strategic colocalization of PVP and drug in the sheath layer yielded a biphasic release profile, characterized by an initial burst followed by a sustained release phase, which successfully eliminated the tailing effect in the late stage. Increasing the drug loading in the outer layer from 1% to 3% significantly enhanced the initial release amount from 65.15% ± 11.19% to 79.26% ± 0.42%. This work establishes a robust material design strategy based on structural and componential control, offering new insights into the development of high-performance nanofibrous systems for tailored drug delivery and functional applications.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.